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Objective: This study aimed to obtain a comprehensive overview on the perception,
attitudes, and experience of European pharmacists with prospective risk assessment
procedures in everyday practice, as well as to identify challenges and solutions. This is
a follow-up study to the surveys on prospective risk assessment previously carried out
within the COST Action 15105 among pharmacists across Europe.
Methodology: In-depth interviews were performed using an interview guide comprising
25 questions. Interviews were transcribed ad verbatim and imported into NVivo 10 for
framework analysis. In NVivo, the interviewswere coded through assigning text segments
to a responding code from a coding tree, covering the full content of the interviews.
Coded text segments were then charted into a matrix, and analyzed by interpreting all
text segments per code.
Results: In total, 18 interviews were conducted. From the framework analysis, 6
codes and 12 sub-codes emerged. Overall, despite citing specific issues pertaining to
its implementation, the interviewees considered multi-stakeholder and multi-disciplinary
prospective risk assessment to be essential. While healthcare professionals reported
being aware of the importance of risk assessment, they cited insufficient knowledge
and skills to be a major obstacle in everyday practice. They also reported inadequate
IT support since a paper-based system is still widely in use, thereby complicating data
extraction to carry out prospective risk assessment.
Conclusion: While prospective risk assessment was found to be valuable, interviewees
also found it to be a resource-intensive and time-consuming process. Due to
resource constraints, it may not be possible or desirable to conduct prospective risk
assessment for every shortage. However, for critical-essential drugs, it is crucial to
have a ready-to-use substitute based on risk assessment. Moreover, potential risks
of substitutes on patient health should be identified before a shortage occurs and the
substitute is dispensed as an alternative.
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Miljković et al. Risk Assessment in Medicine Shortages
INTRODUCTION
The impact on patient morbidity and mortality as a result of
medicine shortages is well-recognized by all key stakeholder
groups including national regulatory authorities globally (1–5).
Medicine shortages pose risks ranging from not being able to
provide themedicine to being forced to administer a non-optimal
substitute, thereby leading to potential medication errors and
other complications (6, 7). To combat against shortages, risks
must therefore be actively differentiated based on: (i) a shortage’s
frequency; (ii) the availability and unavailability of treatment
options and (iii) providing alternatives but not accounting for a
patient’s clinical status (8).
Changing treatment when a shortage occurs brings about
uncertainties as the order, preparation or dispensing procedures
that are needed may also change, which may lead to medication
errors (7). This can breed unfamiliarity with the dosing schedules,
adverse-effect profiles, and treatment efficacy for therapeutic
alternatives among healthcare workers (7, 9, 10). Concerns and
unfamiliarity can be enhanced if therapeutic alternatives have not
been agreed in advance (11).
A number of surveys have been conducted and individual
cases reported to help document the extent of patient harm
stemming from changes in treatment as a result of drug shortages.
In the USA and Canada, the Institute for Safe Medication
Practices (ISMP) provides comprehensive data reports on patient
harm caused by shortages (12–14), and in Europe, several
healthcare professional associations have conducted surveys
showing shortages have a detrimental effect on patient health (4,
5, 15). Similarly, Australian hospital pharmacists have concluded
that shortages do prevent patients from being treated with
less invasive therapy, such as orally administered forms of the
same medicine, which, subsequently, introduce secondary health
complications and prolonged costly hospital stays (16).
As a consequence, medication errors caused by shortages
need to be thoroughly documented, reviewed, analyzed, and
reported as part of safety procedures (7, 17). In addition,
possible therapeutic substitutions need to be predetermined and
categorized in order to avert potential harm, thereby providing
the optimal treatment for a patient in these circumstances (8, 11,
18). A comprehensive risk assessment is the first step in planning
for shortages as this allows for a review of all decision making
processes in a healthcare setting where risks of patient harm stem
from numerous aspects of treatment (19, 20).
Risk assessment is also seen in medicine-shortage reporting
systems, not only to assess the critical need for a medicine
when there are shortages but also for the institution’s ability
to continue to provide patient care. This is illustrated by the
system in Australia where the criticality of a medicine in a
possible shortage situation correlates to its impact on patient’s
health and accordingly registered in the Medicine’s Watch List
(21, 22). Similarly, the European Medicines Agency (EMA) in
its guidance on the detection and notification of shortages, uses
impact analysis for a medicine affected by a shortage, providing
a list of criteria used to assess potential alternatives and the size
of the patient population affected (23). Regardless of the fact
as to whether a medicine shortage is deemed critical or not,
healthcare professionals (HCPs), and regulatory authorities must
identify treatment pathways, including potential rationing, based
on critical assessments so that treatment can be undertaken as
effectively as possible (24).
Currently, apart from processes involving blood transfusion,
chemotherapy, aspects of surgery, medical devices as well
as medicine distribution and prescription, prospective risk
assessment appears uncommon in healthcare (25–30). However,
its usage has been attracting HCPs attention due to progress
that has been made in developing systematic measures to
prevent medication errors in healthcare settings via promoting
prospective risk assessment tools (31–34).
With medicine shortages on the rise (4, 35–37), therapeutic
substitution has become one of the most important steps in
providing continuity of treatment to a patient (7, 11, 38, 39).
Its importance is not only constituted in the substitution itself,
but that this process also represents high risk; as such, it may
cause patient harm if not properly designed, implemented and
regularly evaluated (7). The authors have previously assessed
systematic frameworks and legislative processes for mitigating
against drug shortages (40), the extent of medicine shortages
in Europe, especially in hospitals, (4) and the extent of using
risk-assessment procedures in hospitals to help mitigate the
impact of shortages (34). However, the authors wanted to
build on this given increasing concern with drug shortages
across Europe that needlessly worsen the risk of morbidity and
mortality when no risk-assessment is in place. Consequently,
a series of in-depth interviews were conducted with hospital
pharmacists across Europe to address this matter, aiming to
obtain a comprehensive overview on their perception, attitudes,
and experience in conducting prospective risk assessment
procedures in everyday practice as to address increasing
shortages. The findings of which are usable to help develop
future policies.
METHODOLOGY
Before initiation of this study, the authors received ethical
approval from the Institutional Review Board (IRB) of the
University of Belgrade, Faculty of Pharmacy for the verbal
consent procedure (Nb. 1221/2). Verbal agreement from all
interviewees was also obtained.
This interviewing process built on a previous survey
on prospective risk assessment conducted within the COST
Action 15105 among 34 HCPs from 26 European countries
(34). Interviews were carried out with pharmacists and
pharmacologists working in hospitals, academia and for national
authorities frommember countries of the European Cooperation
in Science and Technology COST Action 15105 countries (41).
Interviewees were selected via the COST Action 15105 network
through purposive sampling and snowballing techniques (42).
The interviewees indicated their consent to be interviewed
by responding to the email. Interviews were conducted in
English via teleconference, telephone or face-to-face based on
the preferences expressed of the interviewee. After informing
interviewees on the purpose of the interview, verbal consent was
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again obtained before continuing. Each interview was audio-
recorded, transcribed ad verbatim and anonymized.
An interview guide was designed for the in-depth interviews.
The questions were based on the results from a preceding
survey on prospective risk assessment (34), and covered
contextual, diagnostic, evaluative, and strategic topics regarding
risk assessment. The interview guide comprised three segments
with 25 questions in total. The first segment addressed
familiarity with risk assessments and information sources on
how to apply risk assessments in everyday practice within
hospitals. The second segment focused on the practical
implementation of risk assessment procedures, detecting risks,
and data transfer. The last segment explored the impact of risk
assessment on prioritizing in the medicine’s substitution process
and overcoming shortages, which was followed by questions
concerning the characteristics of the healthcare setting where the
respondent was employed. The interview guide was piloted at the
Faculty of Pharmacy, University of Belgrade and University of
Leuven, and subsequently refined prior to use in order to enhance
the robustness of the questionnaire.
Interview transcripts were analyzed through framework
analysis (43, 44) using NVivo (45). The interviews were
transcribed ad verbatim by one researcher (NM). At the start
of the analysis, two researchers (NM and EvO) familiarized
themselves with the content of interviews by reading through
the transcripts. When the researchers had any difficulties with
understanding the transcript, they re-listened to the audio-
recording. Several transcripts were subsequently open-coded.
Themes that were identified across the interviews resulted in the
creation of “codes” representing these themes. Two researchers
(NM and EvO) independently used these codes to classify text
segments from the transcripts. After the initial coding was
carried out, the researchers agreed on the final set of codes
and grouped these in a coding tree (Supplementary Material).
The final coding tree was subsequently imported into NVivo
and used to code all transcripts by assigning text segments to a
respective code. After finalizing the coding phase, results were
charted into a matrix where codes formed the columns, and
interviewee numbers the rows (Supplementary Material). The
data in this matrix was subsequently interpreted by identifying
relations between and within codes.
RESULTS
Interviewee Characteristics
Interviews were carried out with 17 pharmacists and 1
pharmacologist (Table 1), representing 18 European countries
(Austria, Belgium, Bosnia and Herzegovina, Croatia, Cyprus,
Estonia, Finland, Germany, Greece, Hungary, Ireland, Italy,
Latvia, Malta, Romania, Serbia, Switzerland, and the UK). Of
these pharmacists, 14 worked in hospitals, 3 for national health
authorities, and 1 pharmacologist working both in academia and
in a healthcare-certification agency. The majority of interviewees
experienced at least one shortage in the week preceding the
interview [28.6%], where 35.7 and 50% of themwere forced to use
more expensive and off-label alternatives, respectively (Table 1).




















(demand or supply related)
All supply 4 (28.6%)
Mostly supply 8 (58.1%)
Supply and demand 2 (14.3%)





Very often 4 (28.6%)





Very often 2 (14.3%)
*Three hospital pharmacists worked for national health authorities, not in hospitals. One
pharmacologist worked in academia and healthcare certification agency.
Insufficient Data, Time, Skills, and Funding
to Perform Risk Assessment
When developing risk assessment strategies, a majority of
interviewees do report using primary methodological data
sources that consisted of: (i) consulting existing materials on
the Internet, which serves as a tool for accessing scientific
publications on risk stratification and therapeutic guidelines; (ii)
official websites of nationalmedicine-regulatory bodies in Europe
and the USA; (iii) healthcare-professional associations; and
(iv) quality and safety information in healthcare departments.
However, the interviewees repeatedly underscored that although
the guiding principles and data used for risk assessment need to
be accurate, independent and objective, this is not always the case:
“For the risk assessment, you need to have reliable information,
otherwise it’s guessing. So, inmany fields we are guessing, because
either there is no clear information, or the responsible authorities
are not willing to give them. Or they have other aims.” (Hospital
Pharmacist, Austria).
By and large, interviewees regard the procedure of risk
assessment as time-consuming and not appropriate for all
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shortages. Whereas, a sufficient number of available generic
alternatives do not elicit much need for risk assessment; it
is typically reserved for those situations with the greatest
clinical impact on patients (including anti-infectives and cancer
medicines) when deciding on an alternative treatment is
more complex.
Time constraints also limit risk assessment resulting in a
multidisciplinary approach not always being feasible. Albeit
alerts regarding possible drug-drug interactions must be done
conservatively to highlight risk and not over-alert (46–48), a lack
of time also limits the ability to pay attention to such alerts. Over-
alerting is viewed as an issue among the interviewees. In order
to avoid “alert fatigue,” they report selective risk assessment as
being generally applied that prioritizes risks but may miss alerts
in the process.
Based on their experience, interviewees also report financial
restraints as being a further obstacle to applying risk assessment
more frequently: “Increasingly getting attention with risk
assessments as an incident reporting. Still underfunded—manual
lifting issues get more funding. The risk assessment is considered
as part of the overall change management documentation
(who needs to know, who needs to be consulted).” (Hospital
Pharmacist, Ireland).
Training to be able to access, analyze and use data still seems to
be an issue. Interviewees from Croatia, Bosnia and Herzegovina,
and Hungary emphasized a lack of HCPs possessing sufficient
knowledge on risk assessment to be able to adequately perform
risk assessment. An interviewee from Ireland also commented
that HCPs need better training on handling data for risk
assessment and risk assessment itself.
The timeliness of data availability is also a concern. Even
when access to data becomes available, it is often too late, as
emphasized by an interviewee from Switzerland. This is borne
out by the fact that only when reaching out for medicine data on
drug availability does such data become accessible. Doubts have
also been conveyed on the ability to conduct risk assessment. As
underscored by an interviewee from Serbia in particular, essential
information on the duration of shortages, as provided by updates
from wholesalers and the industry, is often unavailable.
The importance of risk assessment and its benefits for patients,
helping to achieve a better state of preparedness for potential
shortages, needs to be explained more fully to HCPs. As reported
by interviewees from Estonia and Belgium: “I think awareness of
the fact and the knowledge of the risk assessment, that’s crucial
to me. [. . . ] as soon as you have people that are aware of risk
assessment and see the benefit of it, so that you can use your
scarce resources for the best, it’s just bringing people together.”
(Hospital Pharmacist, Belgium). Moreover, it was also specifically
noted that awareness should be extended beyond the pharmacists
themselves to the health authorities in charge: “If we are the only
ones who think that this is important, this is not going to lead
anywhere. We can only discuss this about it among ourselves.”
(Hospital Pharmacist, Austria).
Even though there may be a general understanding of the
need for risk assessment in mitigating medicine shortages, “the
evidence on the impact of shortage of a drug and its extent
is missing, there is no data” (Hospital Pharmacist, Hungary).
Data on the effectiveness of applied risk assessment procedures
is therefore found to be lacking, thereby complicating the
evaluation of the real impact that risk assessment has as a
mitigation tool. As a result, even communicating the effective
results of implementing risk assessment based on data is a
challenge, as “it should be done in writing, so actual impact can
be seen and prevented” (Hospital Pharmacist, Croatia).
Insufficiently Structured Approaches
Leading to Wide Variation in Risk
Assessment
There is a distinct opinion expressed and shared among
interviewees concerning an apparent gap in responsibility for
“what to do and when you are empowered to make an assessment
and then take the action” (Hospital Pharmacist UK). Generally,
as reported, hospital pharmacists perceive all HCPs as needing
better training on handling data for risk assessment and the risk
assessment itself. In Belgium, Bosnia and Herzegovina, Cyprus
and Romania, no information is available in this area. Given this
feedback, either the data is missing or the guiding documents
on shortage mitigation plans and supporting actions are not
clearly stated by the stakeholders, both of which are concerns to
be addressed.
Interviewees also view a lack of a systematic approach and
the option of using electronic databases in performing risk
assessment to be a concern: “risk assessment is made individually,
based on experience, SmPC (e.g., indications), availability of
drugs, prices and outcomes (side effects). It is not documented
and follow up rarely happens.” (Hospital Pharmacist, Hungary).
Furthermore, the need for IT support is essential for assessment
and data dissemination as noted by one interviewee fromAustria:
“When you have electronic prescribing, implemented in your
hospital, you have much more opportunities to control. If you
don’t it’s more difficult you know. You have to talk to everybody,
to have more meetings, then you have to say, please do this
and you hope that they do that, but you are not sure, you have
no technical instruments to help you in the process.” (Hospital
Pharmacist. Austria).
As highlighted by an interviewee from Italy, the reactive
nature of a retrospective risk assessment—such as with Root
Cause Analysis (RCA)—seems to be not as preventative for
shortages when compared to the prospective form as Failure
Mode and Effects Analysis (FMEA). It is therefore possible to
better comprehend and prioritize risks in time and promptly
react. In particular, prospective risk assessment is also viewed as
a tool which creates faster pathways for medicine substitution
before an actual shortage occurs, thereby bringing about tangible
clinical benefits for patients. Although interviewees report risk
assessment needing to be done in advance, in order to be pro-
actively ready with possible solutions and the risks of providing
a substitute to patients: “risk assessment needs to happen before
an alternative goes to the wards” (Hospital Pharmacist, UK), it is
still widely reported that risk assessment is carried out only when
the shortage and the need do so occurs.
Interviewees asserted that the risk assessment needs “to
be some kind of independent [sic]” and not tailored in the
Frontiers in Medicine | www.frontiersin.org 4 August 2020 | Volume 7 | Article 407
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sense that “everyone conducts the assessment for him/herself
while it should be the other way around” (Hospital Pharmacist,
Germany). Moreover, they point out that risk assessment should
be conducted in a systematic and standardized manner in order
to not merely solve current problems related to shortages, but to
help minimize future problems and equip HCPs as well with the
necessary skills to act more efficiently the next time a shortage
does occur.
A noted concern that needs to be specifically addressed is
that applied risk assessment seems not always to follow scientific
rigor: “My experience is that many people use the risk assessment
in the way they want to use it so it’s in many cases it’s more
politics than really, what is should [sic] be like science.” (Hospital
Pharmacist, Germany). On this basis, as an interviewee from
Finland commented, the risks not only need to be clearly defined,
but multidisciplinary teams must take the patient’s perspective
into account throughout the assessment process.
Depending on the complexity of the substitution, interviewees
from Belgium and Germany reported that a structured decision
making process occurs concerning medicine substitution within
Drug and Therapeutics Committees (DTCs). Whereas, in Italy,
procedures appear to be more applied to compounding, as
well as automated production and dispensing systems compared
to medicine shortages. When a generic substitution occurs,
pharmacists provide data quickly on an alternative into electronic
prescribing systems. Similar to the situation in Estonia, if a
therapeutic alternative is needed, physicians are involved into
the discussion within DTCs and nurses are fully informed of the
substitute’s administration patterns.
In Croatia, Cyprus, Estonia, Hungary, Serbia and Switzerland,
risk assessment is conducted in everyday practice on a case-by-
case basis. In Belgium, Hungary, and Serbia and Belgium risk
assessment takes on differing forms depending on the severity
of the medicine shortage. In Serbia, for example, the healthcare
system performs assessments quickly but only if an appropriate
alternative exists at the immediate healthcare-facility level; if not,
the Serbian Ministry of Health and National Health Insurance
Fund intervene and propose measures based on their own risk
assessment. Depending on the patient population size affected
and the duration of the shortage, DTCs in Hungary take differing
measures to cope with carrying out a quick risk assessment
that provides outputs in terms of whether the needed generic
substitution is feasible. Otherwise, the DTCs and national task
force must be involved, including a more complex analysis
and therapeutic proposals. Risk assessment is incorporated into
a healthcare facility’s accreditation and certification system in
Bosnia and Herzegovina as part of the overall safety management
plan, while health, safety and quality officers in Cyprus provide
training on risk assessment applications in hospital.
An interviewee from Austria (HCP and clinical risk manager)
applies a clinical incident reporting (CIR) system based on
general risk assessment procedures (such as FMEA) in the
overall quality management via electronic tools, but not in the
area of medicine shortages. The belief was also expressed that
risk assessment is currently linked more to procurement and
should be performed prior to tendering procedures in order
to incorporate issues such as the criticality of a medicine,
increasing safety stocks and possible case-by-case analysis, as part
of decision making going forward: “I think pharmacy is in a
very good position to make these decisions, but that should be
done in conjunction with themanagers of the hospital.” (Hospital
Pharmacist, UK).
Unclear Cross-Sharing of Outcomes
Among Stakeholders
Interviewees expressed their concern in relation to not sharing
data on risk assessment outcomes or results among key
stakeholders, viewing it as another challenge in spreading a
culture of performing risk assessment.
Interviewees from Germany and Malta particularly expressed
their concern in relation to not sharing data on risk assessment
outcomes or results among stakeholders. Whilst currently not
in place, an incident reporting system has been noted as being
necessary in Italy in order that HCPs from all healthcare facilities
may share data among themselves, as to be able to perform risk
assessment accordingly. In the context of having a transparent
process of risk assessment, it was noted that “if you want to
reduce risks, you need to disclose them and present existing
risks to the stakeholders, which calls for action” (Hospital
Pharmacist, Switzerland).
Communicating the risk assessments performed appeared
to be conducted via various routes. Most of the interviewees
stated that the internal communication dealing with medicine
shortages, including potential risks, is usually carried out via the
intranet, emails, electronic prescribing systems/Computerized
Physician Order Entry (CPOE), and sometimes via phone calls.
These included email, calls, websites, and other official means
of information exchange, which is currently not perceived as
efficient by a majority of the interviewees. Nevertheless, it is
seen as an important tool in managing shortages successfully
due to the time-sensitive nature of the information being
communicated. Being of this opinion, however, does not mean
that all information is shared equally across cultural lines:
“I think we share a lot, but not everyone shares the same
information, but we are sharing. I’m not sure if this a culture
thing.” (Hospital Pharmacist, Malta) and “It’s not really exchange.
Maybe, it’s still somehow old culture, not to tell, not to say. . . ”
(Hospital Pharmacist, Latvia). It was also stated in Italy that
the regular exchange of information among stakeholders on
incidents provoked by shortages is mandatory and is integrated
into their quality assurance systems and enforced through
policy measures.
There are also ongoing initiatives by HCP bodies to organize
separate channels of communication to better suit their needs
building on current concerns and challenges: “I think you have to
share the information, that’s not discussion about that. However,
not everybody needs every information. You need to choose a
different language.” (Hospital pharmacist, Austria). Initiatives
include organizing lectures for patients in order to provide them
with more information on their medical treatment. Overall, the
way all stakeholders share information and communicate with
each other on detected risks due to shortages should be carried
out in a more transparent and structured way.
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FIGURE 1 | Barriers along the process of risk assessments.
Principal Reasons Cited to Implement Risk
Assessment and the Factors Determining
Its Success
Interviewees cite a number of reasons to implement risk
assessment; chiefly among these include (i) providing as many
patients as possible with adequatemedical treatment; (ii) assuring
the treatment’s continuity; and (iii) avoiding medical errors
and increasing the patient’s safety through incorporating risk
assessment into quality measurement systems.
The principal factors determining the success rate of
risk assessments in a medicine shortage were knowledge
of risk assessment techniques, data reliability, and
communicating risk assessment output among stakeholders. The
barriers also faced when applying risk assessment were identified
throughout the interviews in Figure 1. Table 2 also lists solutions
and challenges to address these factors and barriers.
Associated Major Risks Stemming From
Medicine Shortages
Most interviewees (particularly from Latvia, Belgium, and
Croatia) recognized risks related to overdosing, or sub-dosing
of patients, after substitution taking place due to differences
in the alternative’s strength and the pharmaco-technological
form applied. Furthermore, interviewees agreed that new drug-
drug interactions may emerge after introducing a substitute. As
stated by an interviewee from Serbia, inappropriate medicine
substitution that is solely led by availability may result in
worsening health outcomes in general or increased antimicrobial
resistance, which is a global concern (49–52). It was also noted
in the interviews that patients might not be properly informed
about the alternatives and could be therefore less compliant to
treatment. The risks emerging from a substitution also include
the non-familiarity of HCPs with administration patterns, which
may also bring about adverse events and suboptimal treatment.
DISCUSSION
Beyond placing undue financial burdens on a healthcare system
and its patients, medicine shortages also bear a significant
impact on patient treatment, affecting their health outcomes via
delaying or interrupting treatment or enforcing application of
less efficient treatment (53). Hospital pharmacists, representing
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TABLE 2 | Challenges and solutions for overcoming barriers in applying risk
assessment in shortages.
Factors Challenges Solutions




funding for hiring experts
in risk assessment, train
healthcare professionals in




Provide sufficient funds to
carry out risk assessment in
order to prevent more costly
drug adverse effects that





Lack of experts in the field
of risk assessment among
healthcare professionals
Provide training on risk
assessment techniques with





Not having timely, precise
and reliable information
and feedback from all
stakeholders involved in
shortages processes











only for recording trends and
not for overall risk analysis
Prospective risk
assessment
Not being able to
incorporate all potential
risks that might occur











Lack of willingness for
healthcare professionals


































Insufficient or no transfer
of information on a
substitute’s efficiency or
adverse events profile to
patients






interviewees in this study, provided their insight into shortages,
proposing potential solutions to alleviate their widespread, and
overarching effects.
Engagement Needed to Foster Risk
Assessment
Overall, the findings point to the need for wider multi-
stakeholder engagement and guidance concerning ways to
mitigate shortages in the future. This includes risk assessment
in line with guidance from key groups in the US to
manage the impact and forces that drive shortages (7, 17),
particularly because information on shortages published on
respective national websites is typically outdated. In addition,
interviewees generally learnt about shortages from wholesalers
and manufacturers after it was too late to mitigate the shortage
successfully. This pronounced lack of data sharing between
stakeholders within and across countries to aid the initiation of
risk assessment is in stark contrast to EMA recommendations for
national authorities and stakeholders to mitigate shortages (54).
It would appear that even mandatory (i.e., enforced by the
law) information to be shared on shortages are not equally
and timely disseminated among stakeholders (55, 56). An early
warning system has been recognized widely by HCPs to be
crucial in terms of providing a timely reaction to shortages (57).
Supply-chain actors may enforce a more proactive mitigation of
shortages, which would entail and foster more comprehensive
communication with National Competent Authorities (NCAs)
and HCPs (53).
Moreover, there is a distinct concern regarding medicine
shortages when detailed management and mitigation guidance
is lacking from higher authorities (58, 59). The non-harmonized
approach is reflected in the manner in which shortages are
managed including risk assessment in some European countries
for particular groups of medicines, generally life-saving ones.
Research into what country takes what approach is largely still
novel, at least for Europe. More to the point, as found in
recent research, applied risk assessment lacks such prominence
in practice that there is a reported general state of being unaware
of any governmental or non-governmental strategies of risk
assessment to tackle shortages (34). In spite of the European
Association of Hospital Pharmacists’ (EAHP) Statements of
Hospital Pharmacy underscoring the necessity for contingency
plans to mitigate shortages, any such strategy in Europe is still
uncommon (60). Whereas, there is a conscious need among
HCPs regarding how assessment may detect possible medicines
shortages and lessen their impact on patient health, there is as
of yet inadequate promotion of applying European-wide risk
assessments in a prospective manner (34).
Risk assessment, as a concept in increasing preparedness
for medicine shortages and ameliorating their health impact, is
usually conducted by the manufacturers addressing production
and quality control risks (6). The EMA’s Pharmacovigilance Risk
Assessment Committee (PRAC), on the other hand, stipulates a
wider multi-stakeholder commitment assuring protection, and
promotion of public health (61). In other words, risk assessment
in shortages is also of a public health concern. Since, healthcare
professionals, including pharmacists, participate in the work of
NCA’s, and PRAC under the auspices of EMA, they should be
equipped with the skills necessary to conduct risk assessment,
including sharing their output and fostering multi-stakeholder
engagement (62).
Doing so should also be within the remit of the NCAs that
should closely coordinate via addressing issues related to data
sharing, conducting best practices, and developing strategies, all
in order to provide a safe environment for medicine application
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across Europe and throughout the European regulatory system
for medicines (63). Nonetheless, the EMA’s role in coordinating
the work of expert groups recruited from scientific experts,
healthcare professionals, and patients should also here be
recognized. These groups may propose guidelines and scientific
advice built on experience and expertise in order to supervise
medicine safety (63).
Structured Risk Assessment Needed
The ASHP guidelines state that pharmacists should carry out
available stock assessment in relation to usage patterns and
duration of shortages as well as undertake impact assessments
embodying all the elements of risk assessment (7). However,
a number of the interviewees in this study expressed the view
that risk assessment is mostly conducted in medicine through
the purchasing process rather than in medicine substitution
with therapeutic assessments typically coordinated by hospital
DTCs. This is because therapeutic assessments are not generally
characterized as risk assessment among hospitals in Europe;
however, they do include scenario-based assessments whereby
HCPs or task-force groups assess the current situation of
shortages, predict future shortages, and the potential to mitigate
them to be better prepared in the event of likely shortages in
accordance with ASHP guidance (7). Overall, there is a need
for clear guidelines describing risk assessment itself building on
national guidance (7, 17, 24) as evidenced by the interviewees’
agreeing that risk assessment helps with the prioritization of
both patients’ needs as well as medicines that must be quickly
substituted. This should be conducted especially for critical-
essential drugs in line with the guidance that data on shortages
with a critical patient impact are separately listed with proposed
actions for management (64). Moreover, potential risks for
patient health, which a substitute brings, should be listed before
a shortage actually occurs and a medicine is dispensed as
an alternative especially as specific monitoring features are
not typically listed on shortages databases (1, 7, 17, 56). In
line with this, the interviewees repeatedly reiterated that risk
assessment is of crucial importance for critical medicines,
or medicines needed to treat patients in critical conditions.
Moreover, medicine criticality is based on the availability of
alternatives, indication, and the patient population in the
patient’s respective healthcare settings. This should be taken into
account in procurement processes by creating additional safety
stocks with those medicines that bear the “highest” risk factors.
Facing Challenges and Constraints in
Carrying out Risk Assessment
A typically distinct lack of time and financial resources is an
ongoing issue when seeking to apply risk assessment strategies
in hospitals, which is hindered by a lack of publications
characterizing and quantifying the impact of shortages on HCP
practices, patient health, and overall costs as well as practices
leading to them (17). Such an absence of informative materials
needs to be urgently addressed, although recognizing that there
are only a limited number of experts in the field, it can be
challenging to change the mindset of HCPs who have grown
accustomed to longstanding forms of practice. However, better
patient outcomes are indeed associated with a higher culture
of patient safety, as influenced by HCPs’ beliefs and values (65,
66). Furthermore, not having a digitized system certainly limits
conducting risk assessment as data first needs to be compiled
from non-digital sources, a task that is both time-consuming and
challenging, prior to being applied into analyses.
Enhancing Communication Among
Stakeholders Throughout Risk Assessment
One of the most important aspects of prospective risk assessment
emphasized by the interviewees is communication between
the stakeholders and HCPs involved in this process, which is
currently subject to variation. DTCs and dedicated shortage task
force teams are considered essential in trying to communicate
data efficiently in healthcare settings and avoid problems
encountered by outdated information (67). There would also
seem to be insufficient reference among current EMA guidelines
to risk assessment applicable for HCPs, as well as current EMA
guidance on the data needed by HCPs to help mitigate against
shortages tending to be more reactive than proactive (56),
reflected in the interviewees’ concern about not possessing the
necessary knowledge and skills to perform risk assessment. As
a result, the majority of the interviewees underlined the need
to apply such proactive approaches in the future. In particular,
as stipulated by the US FDA, adjusting e-health patient records,
recoding IT systems to respond to available substitutes, as well
as relabeling and repackaging medicines to assist with managing
future shortages (17). Alongside this, all implemented treatment
protocols in healthcare settings need to go through extensive
revision in order to respond to treatment changes/adjustments
arising from shortages (17). Having said this, HCPs in our
study still consider performing risk assessment ineffective if not
supported by their respective national regulatory bodies as well
as other associated groups.
There is also the evident critical need to share the outputs
of risk assessment to enhance uptake of such strategies along
with general communication regarding shortages in accordance
with numerous mitigation guidelines across countries (7, 17,
22, 68), which entails improving channels of communication
and messages sent to the stakeholders. Moreover, clinical advice
should be provided and any other additional information
needed to prevent risk for patient health arising from shortages,
including data on the duration of action and doses needed
to achieve therapeutic outcomes with alternatives. Such advice
should be regularly updated and be in line with guidance and
activities from regulatory authorities in, as is conducted on a
national level in Australia and the USA (7, 22, 24, 64, 69).
These activities should help address interviewee concerns where
they report delays in, or interruption of, treatment forcing them
to resort to unsafe, and sub-optimal treatments for patients
particularly for cancer patients and emergency medicines, as well
as anesthetics and antibiotics (4, 5, 17). Better coordination and
information among governmental authorities is key.
There has been growing demand among hospital pharmacists
for more timely and accurate information on shortages to better
support patient treatment. In order to attain more reliable and
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accurate information, it would be recommendable that all actors
in the supply chain incorporate their own data on shortages
into a whole that would better foresee potential shortages on
the horizon and communicate them with one another. The
immediate advantages of such a measure would be that the
individual actors would be able to detect a shortage as it appears
(59). Only through a common shared network may information
on shortages be used to combat and anticipate them. This
may consequently improve patients safety and facilitate shortage
mitigation. We have seen this in other situations to improve the
quality and efficiency of prescribing of both new and established
medicines (70–76).
Ultimately, risk assessment performed on medicine shortages
should reach the public in a comprehensive manner and address
their concerns. One of the biggest patient concerns is when
a medicine will be available in order not to have their care
compromised or delayed, especially if a substitute intended to be
used may ultimately prove less effective (77, 78). To help address
these and other patient concerns, tangible information to patients
needs to be provided in a more comprehensive manner.
LIMITATIONS OF THE STUDY
Although this study is qualitative in nature and reports chiefly
on the current views and perceptions of those who are working
as hospital pharmacists in how they mitigate medicine shortages
and where they could see improvement in practices, the study
does not incorporate other viewpoints from a wider variety
of stakeholders involved in addressing medicine shortages on
European scale. As such, there is a predefined limitation of
what the study may conclude. More comprehensive studies that
seek to address risk assessment in order to mitigate medicine
shortages must include a wider range of stakeholders; however,
such a limitation also points to the path that multi-stakeholder
engagement should take in future.
CONCLUSION
Prospective risk assessment gainedmore attention in recent years
with patient safety set as a priority. Whilst HCPs are aware of the
importance of risk assessment as well as available official sources
of information regardingmethodology, there is currently a lack of
knowledge and skills on how to apply risk assessment in everyday
practice. Moreover, the data needed for a proper assessment of
the risks posed by medicine shortages is currently not provided
in a timely-enough manner, which is essential should successful
mitigation be achieved. In future, risk assessment should be
carried out more in a prospective fashion so that emerging risks
from shortages may be better prevented before they even occur.
Notwithstanding, this concept of assessing risk is still not widely
practiced in the area of shortages and needs to be urgently
addressed to better equip HCPs with the tools they need to
manage growing medicine shortages worldwide.
Although the process of prospective risk assessment is often
considered to be time-consuming and not appropriate for
every single shortage, it is necessary, especially for emergency
medicines. In addition, the impact of shortages is not very well-
documented. Both these challenges need to be addressed as being
able to quickly react to an emerging shortage is considered one of
the benefits of prospective risk assessment.
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